Users' guides to the medical literature XIX: Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect

JAMA

Volumn 282, Issue 14, 1999, Pages 1371-1377

  McAlister, Finlay A ^a,d,e   Laupacis, Andreas ^b,c   Wells, George A ^c   Sackett, David L ^a   Guyyat, Gordon ^f   Moyer, Virginia ^g   Naylor, David ^g  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; MEDICAL LITERATURE; MEDICAL RESEARCH; POLICY; PRIORITY JOURNAL; REVIEW; SAMPLING;

EID: 0033552264     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.14.1371     Document Type: Review

References (51)

1. Skolnick AA. Drug firm suit fails to halt publication of Canadian Health Technology Report. JAMA. 1998;280:683-684.
2. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, XIX: applying clinical trial results, A: how to use an article measuring the effect of an intervention on surrogate end points. JAMA. 1999;282:771-778.
3. McDonald O. Medical heuristics. Ann Intern Med. 1996;124:56-62.
4. Rothwell PM. Can overall results of clinical trials be applied to all patients? lancet. 1995;345:1616-1619.
5. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2 : short-term reductions in blood pressure. Lancet. 1990;335: 827-838.
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I [published correction appears in BMJ. 1994;308: 1540]. BMJ. 1994;308:81-106.
7. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure [published correction appears in JAMA. 1995;274:462]. JAMA. 1995;273:1450-1456.
8. Waldo AL, Camm AJ, de Ruyter H, et al, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction [published correction appears in Lancet. 1996;348:416]. Lancet. 1996;348:7-12.
9. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction. Prog Cardiovasc Dis. 1985;27:335-371.
10. Boissel JP, Leizorovicz A, Picolet H, Peyrieux JC. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol. 1990;66:251-260.
11. McAlister FA, Teo KK. Antiarrhythmic therapies for the prevention of sudden cardiac death. Drugs. 1997;54:235-252.
12. Furberg CD, Psaty BM. Calcium antagonists. Am J Hypertens. 1996;9:122-125.
13. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. JAMA. 1998;279:1643-1650.
14. Guyatt GH, Sackett DL, Sinclair JC, Hayward RC, Cook DJ, Cook RJ, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, IX: a method for grading health care recommendations [published correction appears in JAMA. 1995; 275:1232]. JAMA. 1995;274:1800-1804.
15. Canadian Task Force on the Periodic Health Examination. The Periodic Health Examination, 2: 1987 update. CMAJ. 1988;138:618-626.
16. Canadian Task Force on the Periodic Health Examination. The Periodic Health Examination, 2: 1987 update. CMAJ. 1988;138:618-626.
17. Cook DJ, Guyatt GH, Laupacis A, Sackett DL, Goldberg RJ. Clinical recommendations using levels of evidence for antithrombotic agents. Chest. 1995;108(4 suppl):227S-230S.
18. Donner A. Approaches to sample size estimation in the design of clinical trials. Stat Med. 1984;3:199-214.
19. Naguib M, el Bakry AK, Khoshim MH, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy. Can J Anaesth. 1996;43:226-231.
20. Korttila K, Clergue F, Leeser J, et al. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting. Acta Anaesthesiol Scand. 1997;41:914-922.
21. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-373.
22. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344: 1383-1389.
23. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
24. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
25. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
26. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349-1357.
27. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia [published correction appears in Am J Cardiol. 1998;82: 128]. Am J Cardiol. 1998;81:582-587.
28. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 1998;97:1446-1452.
29. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
30. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-1445.
31. Fager G, Wiklund O. Cholesterol reduction and clinical benefit: are there limits to our expectations? Arterioscler Thromb Vasc Biol. 1997;17:3527-3533.
32. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality [published correction appears in BMJ. 1993;306:1648]. BMJ. 1993;306:1367-1373.
33. Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH, for the Harvard Atherosclerosis Reversibility Project Research Group. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol. 1995;76:78C-85C.
34. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683-691.
35. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78-84.
36. Yusuf S, Wittes J. Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93-98.
37. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:356-362.
38. Psaty BM, Siscovick DS, Weiss NS, etal. Hypertension and outcomes research: from clinical trials to clinical epidemiology. Am J Hypertens. 1996;9:178-183.
39. Marshall WJ. Administrative databases: fact or fiction? CMAJ. 1998;158:489-490.
40. Sackett DL, Haynes RB, Gent M, et al. Compliance. In: Inman WH, ed. Monitoring for Drug Safety. Philadelphia, Pa: Lippincott; 1980:427-438.
41. Gruppo Italiano per lo Studio della Soprawivenza nell' Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65-71.
42. Third International Study of Infarct Survival Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
43. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: across-national study. JAMA. 1998;279:1458-1462.
44. Dans AL, Dans LF, Guyatt GH, Richardson S, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, XIV: how to decide on the applicability of clinical trial results to your patient. JAMA. 1998;279:545-549.
45. Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland D, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, XIII: how to use an article on economic analysis of clinical practice, A: are the results of the study valid? JAMA. 1997;277:1552-1557.
46. Naylor CD. Williams JI, Basinski A, Goel V. Technology assessment and cost-effectiveness analysis: misguided guidelines? CMAJ. 1993;148:921-924.
47. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? CMAJ. 1992;146:473-481.
48. Gotto AM Jr. Cholesterol management in theory and practice. Circulation. 1997;96:4424-4430.
49. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease [published correction appears in Arch Intern Med. 1998;158:1228], Arch Intern Med. 1998;158:655-662.
50. Lacour A, Derderian F, LeLorier J. Comparison of efficacy and cost among lipid-lowering agents in patients with primary hypercholesterolemia. Can J Cardiol. 1998;14:355-361.
51. Tu JV, Naylor CD. Choosing among drugs of different price for similar indications [published correction appears in Can J Cardiol. 1998;14:662]. Can J Cardiol. 1998;14:349-351.